Sparsentan

Specifications

254740-64-2CAS Number

839-064-7EC Number

2-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-(ethoxymethyl)phenyl]-N-(4,5-dimethyl-1,2-oxazol-3-yl)benzenesulfonamideIUPAC Name

C32H40N4O5SChemical Formula

592.8 g/molMolecular Weight

sparsentan; 254740-64-2; RE-021; FILSPARI; PS433540; esparsentan; PS-433540; sparsentanum; 9242RO5URM; (1,1'-Biphenyl)-2-sulfonamide, 4'-((2-butyl-4-oxo-1,3-diazaspiro(4.4)non-1-en-3-yl)methyl)-N-(4,5-dimethyl-3-isoxazolyl)-2'-(ethoxymethyl)-; 4'-((2-butyl-4-oxo-1,3-diazaspiro(4.4)non-1-en-3-yl)methyl)-N-(4,5-dimethyl-1,2-oxazol-3-yl)-2'-(ethoxymethyl)biphenyl-2-sulfonamide; RefChem:56752; 4'-((2-butyl-4-oxo-1,3-diazaspiro(4.4)non-1-en-3-yl)methyl)-N-(4,5-dimethyl-1,2-oxazol-3-yl)-2'-(ethoxymethyl)-(1,1'-biphenyl)-2-sulfonamide; Sparsentan (RE-021); Sparsentan [USAN]; 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4,5-dimethylisoxazol-3-yl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonamide; RE 201; 2-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-(ethoxymethyl)phenyl]-N-(4,5-dimethyl-1,2-oxazol-3-yl)benzenesulfonamide; CHEMBL539423; MFCD16628036; 4'-[(2-Butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(ethoxymethyl)[1,1'-biphenyl]-2-sulfonamide; retrophin; UNII-9242RO5URM; Spashentan; C32H40N4O5S; Filspari (TN); DARA; compound 7 [PMID 15634011]; PS 33540; SPARSENTAN [INN]; SPARSENTAN [WHO-DD]; Sparsentan(PS433540)?; SCHEMBL535109; Sparsentan (JAN/USAN/INN); GTPL8448; orb1301859; SCHEMBL29706489; CHEBI:229526; GLXC-15418; EX-A3048; BDBM50175523; s6665; AKOS040758741; CS-7947; DB12548; SB16876; DARA-a (Dual Acting Receptor Antagonist of angiotension and endothelin receptors); PS-433540;RE-021;DARA; AC-35179; DA-67132; HY-17621; MS-30544; SY335644; PS 433540; NS00070334; Sparsentan (PS-433540,RE-021,DARA); T5355; D11776; F77045; L023324; Q27088845; 2-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-(ethoxymethyl)phenyl]-N-(4,5-dimethylisoxazol-3-yl)benzenesulfonamide; 4 inverted exclamation mark -[(2-Butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2 inverted exclamation mark -(ethoxymethyl)-[1,1 inverted exclamation mark -biphenyl]-2-sulfonamide; 4''''-(2-Butyl-4-oxo-1,3-diaza-spiro[4.4]non-1-en-3-ylmethyl)-2''''-ethoxymethyl-biphenyl-2-sulfonic acid (4,5-dimethyl-isoxazol-3-yl)-amide; 4''-(2-Butyl-4-oxo-1,3-diaza-spiro[4.4]non-1-en-3-ylmethyl)-2''-ethoxymethyl-biphenyl-2-sulfonic acid (4,5-dimethyl-isoxazol-3-yl)-amide; 4'-((2-BUTYL-4-OXO-1,3-DIAZASPIRO(4.4)NON-1-EN-3-YL)METHYI)-N-(4,5- DIMETHYLISOXAZOL-3-YL)-2'-(ETHOXYMETHYL)BIPHENYL-2-SULFONAMIDE; 4'-((2-butyl-4-oxo-1,3-diazaspiro(4.4)non-1-en-3-yl)methyl)-N-(4,5-dimethyl-1,2-oxazol-3-yl)-2'-(ethoxymethyl)-2-biphenylsulfonamide; 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-1,2-oxazol-3-yl)-2'-(ethoxymethyl)[biphenyl]-2-sulfonamideSynonyms